0 S0120521080001 chentl S0120522100005 liuchuang S0120523080003 lijy7|2023 10 26 1 6 GLP-1 GLP-1 1 2-3/1/1/2 Retatrutide 3 CagriSema Versanis Bimagrumab ActRIIA/B 4 GLP-1 NASH 23 5 Aging Cell GLP-1 5 VS VS GLP-1 GLP1 GLP-1 200 40 5000 4000/1 GLP-1-2 26 YWDWvMnQpMpOpRnOsPpQmNbRbP9PsQmMtRoNjMmNpPeRoMqP8OqQvMxNsQqOuOpOpP2 0102030405 GLP-1 CONTENTS 3 01 4 BMI WC WHR WHtR BMI BMI BMI 20 18739 BMI 6 5 WHO BMI 18.5 BMI 18.5 18.5BMI 24.0 18.5BMI 25.0 24.0BMI 28.0 25.0BMI 30.0 BMI28 BMI30 WHO BMI WHO kg/m2 BMI 24 24-28 28 4.7%14.5%28.3%3.5%8.8%17.1%28.1%34.6%35.3%13.0%38.0%54.9%LDL-L 15.6%23.3%24.6%23.2%56.2%73.5%BMI 18739 BMI 5 1990 1%1992 16.4%3.6%20.0%2018 34.3%16.4%50.7%2020 2020 617 6/20%10%2030 18/65.3%717 31.8%6 15.6%2020 16-60 9 65%5.8 0%1%2%3%4%5%0%10%20%30%40%50%60%70%1992 2004 2018 2030E肥胖、超重人数占比（%）CAGR%资料来源：中国居民肥胖防治专家共识，德邦研究所 6 5000 6 02GLP-1 7-Xenical Qsymia Contrave Saxenda Wegovy Vivus FDA 1999 2012 2014 2014 2021 12 12 12 120mg 3/7.5/46 1/8/90 2/3.0mg 1/2.4mg 1/2003 III lancet NCT00554216 NCT00532779 NCT01272219 NCT03548935 BMI 28-47 BMI 35BMI 36.2 4.5-36.1 4.3 BMI 38.3 6.4 38.3 6.3 BMI 37.8 6.7 38.0 6.5 vs vs vs-vs vs vs 52:-10.2%vs-6.1%56-10.92%vs-5.1%vs-1.55%56-6.2%vs-2.1%56-8.0%vs-2.6%68-14.9%vs-2.4%AE 84.54%vs 80%vs 72.9%;SAE 2.54%vs 2.5%vs2.73%AE 85.9%vs 75.2%;SAE 3.8%vs 2.3%AE 80.3%vs 63.3%;SAE 6.2%vs 5.0%AE 89.7%vs 86.4%SAE 9.8%vs 6.4%26.6%vs 1.3%22.1%vs 6.7%/20.0%vs 2.9%7.7%vs 0.9%14%vs7.9%vs6.8%12.3%vs15.8%vs10.9%7.83%vs 5%vs 4.87%19.1%vs 7.1%11.2%vs 8.7%5.5%vs 3.7%40.2%vs 14.7%8.6%vs 9.8%20.9%vs9.3%23.4%vs 9.5%8.7%vs 12.2%31.5%vs 15.9%Qsymia/-8.2%vs-3.9%-7.1%vs+0.1%-4.2%vs-1.5%-2.6%vs-1.9%-13.54%vs-4.13%-8.35%vs-0.48%-6.16%vs-1.06%-2.83%vs-0.42%资料来源：Wilding JPH,et alOnce-Weekly Semaglutide in Adults with Overweight or Obesity，Xavier Pi-Sunyer,et alA Randomized,Controlled Trial of 3.0 mg of Liraglutide in Weight Management，Caroline M ApovianA randomized,phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors(COR-II)，NIH，Clincaltrials，各药品说明书，医药魔方Nextpharma，德邦研究所2.1 GLP-1 GLP-1 GLP1 8 020406080100120140160180I期临床 I/II期临床 II期临床 II/III期临床 III期临床 GLP-1 Saxenda Wegovy III GLP-1 5.4%12.5%GLP-1 GLP-1 GLP-1R 162 32.7%资料来源：医药魔方，德邦研究所GLP-1 2.1 GLP-1 9 13 3 3463 3012345672016 2017 2018 2019 2020 2021 2022 2023数量 GLP-1 BD 资料来源：医药魔方，insight等，德邦研究所 2023-06-13 GMA106 5700 2023-03-09;-2023-02-22 Scohia Pharma SCO-094;28002022-12-06();-2022-06-23 Julphar;-2022-04-25 FGF21-Fc();FGF21/GLP-1-Fc();3.42 2023 7 GLP-1/GLP-1R BD 2023 3 2023 6 13 GMA106 5700 GMA106 GLP-1 3 BD GLP-1/GLP-1R BD 2023 III GLP-1 GLP-1 BD 2022-2023 GLP-1 GLP-1 2.1 GLP-1 10 GLP-1 incretin-1 GLP-1 GIP GLP-1 GLP-1 GLP-1 L GLP1 GLP-1 2 DPP-4-4/GLP1 GLP-1 资料来源：Filip K KnopGLP-1 receptor agonists:The cardiovascular benefits beyond glucose control，德邦研究所2.1 GLP-1 11 0.25mg 2.4mg 5()-16 2.5mg 15mg 6()-20 2mg/3mg 6mg/9mg 3()-8 GLP1 2.1 GLP-1 资料来源：胰高血糖素样肽1受体激动剂类药物用药指导及药物服务路径(2023版)，Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial，信达生物官网，德邦研究所,8),;,(1/1001/10),1,1/10001/10)LEADER,3/min;REWIND,1.87/min;SUSTAIN6,2.02.5/min,),1/10001/100),1/100001/100),-MTC,MTC-,GLP-1RA 1/100001/1000),GLP-1 GLP-1RA Kendall DM GLP-1RA LEADER()STEP 4 20 48 GLP-1 12 GLP-1 资料来源：Minzhi YuBattle of GLP-1 delivery technologies，德邦研究所；注：索马鲁肽即司美格鲁肽2.2 GLP-1 1 GLP-1 GLP-1 GLP-1 GLP-1+GLP-1 27 Lys Arg C16 DPP-4+8 Ala-Aib DPP-4 C16 C18 GLP-1 13 资料来源：胰高血糖素样肽-1受体激动剂（GLP-1RA）临床应用医药专家共识J,曾英彤,王妍,张宏亮，德邦研究所 GLP-1 GLP-1 GLP-1()GLP-1 GLP-1RA exendin-4(GLP-1)GLP-1 GLP-1 GLP-1 2.2 GLP-1 1 GLP-1/%-4 53 2.4 2 5 g 10 g/GLP-1 100 11 3 0.1 TID 0.1 0.2 TID exendin-4 50 3 1 10 d 20 d/GLP-1 97 13 1 0.6 1.2 1.8 qd/GLP-1 94 7 1 0.25 0.5 1 qw/GLP-1 90 4.7 1 0.75 0.75 mg 1.5 mg qw-4 53 2.4 h 1 2 2/GLP-1 144155 1 0.1 0.1 0.2 qw 14 资料来源：AMGEN官网材料，2022AHA，insight官网，药融云，华人抗体公众号，德邦研究所 AMG133 GIPR GLP-1 GLP-1R/GIPR AMG133 GLP-1R GIPR GIPR BMI GIPR AMG133 14-25 2022 11 7 AHA AMG133 3 12 7.2%14.5%2023 9 6 AMG133 2.2 GLP-1 1-AMG133 AMG133 AMG133 15 FGF21;GLP-1,6GLP-1R,217GLP-1R;GCGR,GLP-1R;GCGR;GIPR,8GLP-1R;GIPR,35GLP-1R;GLP-2R,2GLP-1R;NPY2R,2insulin;GLP-1R,11其他双/多靶,29FGF21;GLP-1 GLP-1R GLP-1R;GCGRGLP-1R;GCGR;GIPR GLP-1R;GIPR GLP-1R;GLP-2RGLP-1R;NPY2R insulin;GLP-1R 其他双/多靶/GLP-1/340 GLP-1 123/GLP-1R/GIPR GLP-1R/GCGR,/资料来源：医药魔方，德邦研究所 GLP-1 2023.09.23 2.3 GLP-1 2 药品名称 靶点 研发机构 全球阶段 中国阶段替尔泊肽 GLP-1R;GIPR Eli Lilly 批准上市 申请上市玛仕度肽 OXM;GLP-1R;GCGR 信达生物;Eli Lilly III 期临床 III 期临床retatrutide GLP-1R;GCGR;GIPR Eli Lilly III 期临床 III 期临床cotadutide OXM;GLP-1R;GCGR AstraZeneca II/III 期临床 II/III 期临床maridebart cafraglutide GLP-1R;GIPR Amgen II 期临床 申报临床RG7697 GLP-1R;GIPRNovo Nordisk;Marcadia Biotech(Roche)II 期临床 临床前pemvidutide GLP-1R;GCGR Altimmune II 期临床 临床前pegapamodutide OXM;GLP-1R;GCGRTransition Therapeutics(OpkoHealth);领康医药;Eli LillyII 期临床 临床前NN9389 GLP-1R;GIP Novo Nordisk II 期临床 临床前MK-8521 GLP-1R;GCGR Merck&Co.II 期临床 临床前MEDI4166 GLP-1;PCSK9 AstraZeneca II 期临床 临床前MAR701 GLP-1R;GIPR Marcadia Biotech(Roche)II 期临床 临床前efocipegtrutideGLP-1;GLP-1R;GIP;glucagon;GCGR;GIPRHanmi Pharmaceuticals II 期临床 临床前dapiglutide GLP-1R;GLP-2R Zealand Pharma II 期临床 临床前CT-868 GLP-1R;GIPR Carmot Therapeutics II 期临床 临床前bamadutide GLP-1R;GCGR Sanofi II 期临床 临床前efinopegdutide OXM;GLP-1R;GCGRHanmi Pharmaceuticals;Merck&Co.;Johnson&JohnsonII 期临床 I 期临床survodutide GLP-1R;GCGRBoehringer Ingelheim;Zealand PharmaII 期临床 II 期临床HS-20094 GLP-1R;GIPR 豪森药业 II 期临床 II 期临床HRS9531 GLP-1R;GIPR 恒瑞医药 II 期临床 II 期临床HR17031 insulin;GLP-1R 恒瑞医药 II 期临床 II 期临床HEC88473 FGF21;GLP-1 东阳光药 II 期临床 II 期临床BGM0504 GLP-1R;GIPR 博瑞医药 II 期临床 II 期临床 GLP-1 II 2023.09.23 16 GIPR GLP-1R Laurie L.Baggio Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease GIP 42 K GLP-1 GIP GIP GIPR GIPR+GIP GLP-1 OXM GLP-1R GCGR GLP-1R Alessandro Pocai Action and therapeutic potential of oxyntomodulin OXM-1 GLP-1R GCGR GCGR GLP-1R GCGR GLP1R GLP1R 资料来源：Yutaka SeinoGIP and GLP-1,the two incretin hormones:Similarities and differences，Alessandro PocaiAction and therapeutic potential of oxyntomodulin，德邦研究所2.3 GLP-1 2 GIPR GCCR GLP1 17 GIPR/GLP-1R GLP-1-1 GIP Trizepatide 2022 4 Tirzepatide III SURMOUNT-1 2539 BMI30 BMI27 72 5/10/15mg 16%/21.4%/22.5%10/15mg 20%tirzepatide 0.93 72 0.70 0.95 0.88:10/15mg 19.4 7.6 19.9 7.8 礼来Trizepatide由GIP和GLP-1整合而来资料来源：Wang LDesigning a Dual GLP-1R/GIPR Agonist from Tirzepatide:Comparing Residues Between Tirzepatide,GLP-1,and GIP，德邦研究所2.3 GLP-1 2-Trizepatide GIPR/GLP-1R 资料来源：礼来官网，德邦研究所72周不同剂量Trizepatide体重减轻比例（%）Trizepatide不同减重比例人数占比（%）18 Mazdutide IBI362 GLP-1R/GCGR 2019 8IBI362 mazdutide GLP-1R GCGR OXM GLP-1R mazdutide GCGR Mazdutide II 2022 6 Mazdutide II 3.0mg 4.5mg 6.0mg 24 248 3.0mg 4.5mg 6.0mg Mazdutide 24 3.0mg 4.5mg 6.0mg 8.3%11.6%12.6%mazdutide 2022 10 mazdutide III 23 24 0%2%4%6%8%10%12%14%3.0mg 4.5mg 6.0mg 安慰剂体重减轻比例（%）0.0%20.0%40.0%60.0%80.0%100.0%5%10%3.0mg 4.5mg 6.0mg 安慰剂MazdutideII%MazdutideII%资料来源：信达生物公众号，德邦研究所2.3 GLP-1 2-Mazdutide GLP-1R/GCGR 19-Trizepatide 15mg 72 17.8%GLP-1R 2.4mg 68 12.5%-Mazdutide 3mg vs 4.5mg vs 6mg 24,8.26%11.60%12.62%68%17.8%16.4%11.9%12.5%12.6%11.6%8.3%5.8%5.5%4.2%5.4%0%4%8%12%16%20%资料来源：John P.H.WildingOnce-Weekly Semaglutide in Adults with Overweight，Ania M.JastreboffTirzepatide Once Weekly for the Treatment of Obesity，Xavier Pi-SunyerA Randomized,Controlled Trial of 3.0 mg of Liraglutide in Weight Management，Linong JiIBI362(LY3305677),a weekly-dose GLP-1 and glucagon receptor dual agonist,in Chinese adults with overweight or obesity:A randomised,placebo-controlled,multiple ascending dose phase 1b study信达生物公众号，德邦研究所85.1%88.9%90.9%86.4%63.2%58.1%82.5%80.3%68.5%78.1%83.5%69.1%33.1%19.4%49.2%50.80%48.0%66.6%70.6%50.5%14.4%30.0%50.1%56.7%32.0%15.3%32.3%36.2%0%10%20%30%40%50%60%70%80%90%100%5%10%15%20%25%2.3 GLP-1 2 202.3 GLP-1 2-Retatrutide(GCGR/GIPR/GLP-1R)资料来源：TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial.Ania M.Jastreboff.et al，德邦研究所 Retatrutide48 24.2%2023 6 26 NEJM Triple Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Retatrutide GCGR/GIPR/GLP-1R 12mg 48 24.2%Retatrutide 2mg 4mg 24 Retatrutide 212.4 GLP-1 3-CagriSema+CagriSema HbA1c 资料来源：诺和诺德2023 ADA交流PPT，53-OR:Efficacy and Safety of Coadministered s.c.Semaglutide and s.c.Cagrilintide in Type 2 Diabetes，JUAN P.FRIAS.et al，德邦研究所 CagriSema 32 15.6%CagriSema CagriSema 2.4 mg amylin cagrilintide 2.4 mg semaglutide 2023 ADA CagriSema II 2 CagriSema 32-15.6%15%3 HbA1c CagriSema-2.2%VS-1.8%VS-0.9%CagriSema 21 68%22 71%24 80%2 3 222.4 GLP-1 3-资料来源：赛柏蓝公众号，insight数据库公众号，Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity，德邦研究所 2023 7 14 Versanis Bimagrumab ActRIIA/B 2b/23 STAT Breakthrough 40%Bimagrumab Bimagrumab BYM338 II ActRII 10 mg/kg 1200 mg 48 4 6.5%5.9 kg 20.5%7.5 kg T2D ActRIIA LAE102 1/ActRIIA/B Bimagrumab Bimagrumab 232.5 GLP-1 4/,GLP-1 GLP-1 0 10 20 30脂肪肝心血管疾病阿尔茨海默病帕金森病PET显像胰岛细胞瘤慢性肾病肝纤维化短肠综合征I期临床I/II期临床II期临床II/III期临床III期临床申请上市批准上市 GLP-1 2030 900 资料来源：医药魔方，辉瑞官网,Glucagon-like peptide-1 receptor agonists to expand thehealthy lifespan:Current and future potentials，德邦研究所 GLP1 23 5 Aging Cell GLP1 GLP1 GLP-1 2030 900 270 GLP-1 242.5 GLP-1 4/,GLP1 GLP1 NASH 数据来源：诺和诺德财报，新康界，德邦研究所 252.5 GLP-1 4/,NASH 资料来源：药明康德，医药魔方，德邦研究所 NASH NASH NAFLD NASH F2 F3 FDA NASH GLP-1 NASH III GLP-1-1 GLP-1/efinopegdutide GLP-1 NASH()Novo Nordisk III Eli Lilly II efinopegdutide Hanmi Pharmaceuticals;Merck&Co.;Johnson&Johnson IIefocipegtrutide Hanmi Pharmaceuticals II survodutide Boehringer Ingelheim;Zealand Pharma II ecnoglutide;I danuglipron Pfizer I pemvidutide Altimmune I AZD9550 AstraZeneca I HEC88473 I NNC0194-0499+Novo Nordisk I PB-718;I SCO-094 Scohia Pharma;Takeda Pharmaceuticals;I VK2735 Viking Therapeutics I NASH GLP-1 26 资料来源：Semaglutide 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis:a randomised,placebo-controlled phase 2 trial，Prof Rohit Loomba MD，et al，默沙东公告，药明康德，德邦研究所 NASH-2023 6 Gastroenterology&Hepatology NASH II 2.4 mg NASH 48 23 49%30%13%-Efinopegdutide 2023 6 MSD EASL-1 GLP-1/efinopegdutide NAFLD IIa efinopegdutide GLP-1 Efinopegdutide 24 72.7%42.3%efinopegdutide NASH 2.5 GLP-1 4/,NASH 27 资料来源：药明康德，医药魔方，国家药物临床试验登记与信息公示平台，德邦研究所 GLP-1 III 2021 11 III CTR20212849()Novo Nordisk IIIRybelsus Emisphere Technologies III GX-G6;Genexine pegsebrenatide Neuraly;DA-JC4 DA5-CH GLP-1/GIP/glucagon receptor agonist Lancaster University;GLP1R agonist AVVA Pharmaceuticals KP405 Kariya Pharmaceuticals+GLP-1 GLP-1 2023.07 2.5 GLP-1 4/,282.6 GLP-1 6 VS GLP-1 GLP-1 GLP-1 GLP-1 SNAC N-8-2-pH GLP-1 1 29 资料来源：NOVO官网，德邦研究所 2023 ADA III OASIS 1 PIONEER PLUS 2 OASIS 1 BMI30 BMI27/2 III 50 mg 1 68 17.4%1.8%50 mg 92%86%PIONEER PLUS 2 25 mg 50 mg III 52 50mg HbA1c 2.2%50mg 52 9.2%OASIS 1 PIONEER PLUS 2.6 GLP-1 6 VS 30 GLP-1 2023.07 资料来源：医药魔方，德邦研究所 2023 6 27 16 GLP-1 Orforglipron II III GSBR-1290 RGT-075 TTP273 HRS-7535 II()Orforglipron Eli Lilly;Chugai Pharmaceutical II;III GSBR-1290 II;II RGT-075 II II TTP273 Daewon Pharmaceutical;II II Danuglipron Pfizer II;II Lotiglipron Pfizer;Sosei II;II Pegapamodutide Eli Lilly;Transition Therapeutics;II II NPM-119 Vivani Medical II II HRS-7535 II II MDR-001 II;I/II CT-996 Carmot Therapeutics;II I ECC5004 II;I HDM1002 II I K-757 Kallyope I K-833 Kallyope;II I XW014 II;I 2.6 GLP-1 6 VS 16 31 资料来源：辉瑞官网，Efficacy and Safety of OralSmall Molecule Glucagon-Like Peptide 1 ReceptorAgonist Danuglipron for Glycemic Control Among Patients With Type 2 DiabetesARandomized Clinical Trial，Aditi R.Saxena.et al,insight数据库，德邦研究所 GLP-1R Danuglipron Lotiglipron Lotiglipron Danuglipron PF-07081532 Danuglipron 2023 5 22 GLP-1 danuglipron 2b JAMA 411 2 5 2.5mg 10mg 40mg 80mg 120mg 16 120mg Hb1Ac 1.16%4.17kg Lotiglipron 2023 6 26 lotiglipron 1 C3991040 NCT05671653 C3991047 NCT05788328 I II Lotiglipron 2.6 GLP-1 6 VS Lotiglipron 32资料来源：Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes:A Randomized Clinical Trial.Aditi R Saxenn.et al，Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity,Sean Wharton et al，Novo官网，德邦研究所 GLP-1 Orforglipron Danuglipron Oral semaglutide II II III PIONEER PLUS III OASIS 1 272 411 1606 667 1 T2D HbA1c6.5%2 BMI 22.5 24.5 45.4 2 HbA1c 8.0 10.5%/2 108.7 kg 91.3 kg 96.4kg 105.4kg 12 mg,24 mg,36 mg,or 45 mg or placebo2.5mg,10mg,40mg,80mg,120 mg or placebo 50 25 14 mg 50 mg 1 1 36 16 52 68%-9.4-12.5-13.5-14.7-2.3 0.02 0.06 1.16 2.48-4.60 0.43-9.2-7.0-4.5-17.4-1.8 5%72 90 92 90 24 6 10 18 22 47 2 75.7 63.2 44.1 89.2 24.5 10%47,62,75 69 9/43.9 32.4 15.7 74.7 11.8 15%22 33 43 48 1/58.5 5.3%0-10%0%1-8%2%8.2 10.7 9.9 9.6 8.7 10-21%2%3%-34%8%12.7 12.4 10.1 5.7 3.62.6 GLP-1 6 VS 33 03 340%100%200%300%400%500%600%礼来 诺和诺德 Tirzepatide Tirzepatide better Wegovy OzempicWegovyMounjaro Wegovy CDMO Tirzepatide 资料来源：Wind，Drugs，医药魔方，健康界，德邦研究所3.1 GLP-1 GLP1 5000 4000 35 5000 8 8 2023 152.72 7%83.12 28%GLP-1 Tirzepatide Tirzepatide 2022 5 FDA 2023 15.48 2023 40 2023 22 334 339 15%5000 资料来源：Wind，医药魔方，礼来半年报，诺和诺德公告，德邦研究所 2023 8 8 CVOT 8 8 SELECT 2.4 mg MACE 2.4 mg MACE 20%CVOT GLP-1 17%4313 3.1 GLP-1 GLP1 5000 4000 36 资料来源：辉瑞官网,德邦研究所 2030 GLP-1 2 900 PD-1/L1 2 350-400 500-550 GLP-1 3.2 GLP-1 GLP1 37 资料来源：诺和诺德公告，礼来2023H1财报PPT，医药魔方，德邦研究所-2022 772.37 113.46 93.44%2021 84%,2023 90 23 200-2022 5 FDA 2023 15.48 2023 40 2020-2023H1 亿美元（以1 丹麦克朗兑换0.1469 美元换算）3.3 GLP-1 2023H1 2023 H1 38 GLP-1 II 2023.09.23 1 2 GLP-1R Novo Nordisk GLP-1R Novo Nordisk GLP-1R;GIPR Eli Lilly Rybelsus GLP-1R Novo Nordisk III GLP-1R Eli Lilly;AstraZeneca;Bristol-Myers Squibb IIIretatrutide GLP-1R;GCGR;GIPR Eli Lilly III orforglipron GLP-1R Eli Lilly;Chugai Pharmaceutical III cagrilintide+semaglutide amylin;GLP-1R Novo Nordisk III GLP-1R Eli Lilly II survodutide GLP-1R;GCGR Boehringer Ingelheim;Zealand Pharma II pemvidutide GLP-1R;GCGR Altimmune II AMG 133 4 GLP-1R;GIPR Amgen II lotiglipron GLP-1R Pfizer;Sosei II K-833 GLP-1R Kallyope II K-757 GLP-1R Kallyope II efinopegdutide GLP-1R;GCGR Hanmi Pharmaceuticals;Merck&Co.;Johnson&Johnson II dapiglutide GLP-1R;GLP-2R Zealand Phara II danuglipron GLP-1R Pfizer II CT-868 GLP-1R;GIPR Carmot Therapeutics II Bydureon GLP-1R AstraZeneca;Bristol-Myers Squibb;Alkermes;Eli Lilly II 资料来源：医药魔方，德邦证券研究所3.4 GLP-1 20 II 39 04 40 8766444333333330 2 4 6 8 10华东医药礼来制药诺和诺德恒瑞医药联邦制药和泽医药正大制药集团阿斯利康通化东宝药业赛诺菲制药石药集团甘李药业豪森药业东阳光药业Zealand Pharma药品数量4.1 资料来源：医药魔方，insight，德邦研究所 GLP-1 GLP-1 3 GLP-1/GLP-1R IND GLP-1 2023 2023 6 14 2022 GLP-1 GLP-1/GLP-1R 2023 6 14 GLP-1 99 10 GLP-1 GLP-1 GLP-1 II/III期临床,1III期临床,20II期临床,11I期临床,27批准上市,11申报临床,25申请上市,4II/III期临床 III期临床 II期临床 I期临床批准上市 申报临床 申请上市注：不含临床前、申请临床和无申报项目141535 354705101520253035404550IND 41 1 2 GLP-1R Novo Nordisk GLP-1R GLP-1R Eli Lilly Bydureon GLP-1R AstraZeneca;Bristol-Myers Squibb;Alkermes;Eli Lilly Rybelsus GLP-1R Novo Nordisk GLP-1R III GLP-1R;III GLP-1R III GLP-1R ConjuChem Biotechnologies III rExenatide-4 GLP-1R;III GX-G6 GLP-1R;Genexine III efpeglenatide GLP-1R Hanmi Pharmaceuticals;Sano